We Offer Worldwide Shipping
Login Wishlist

6alpha-Hydroxynidorellol

$905

Brand : BIOFRON
Catalogue Number : AV-B02341
Specification : 97%
CAS number : 70387-38-1
Formula : C20H34O3
Molecular Weight : 322.48
PUBCHEM ID : 91884829
Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

AV-B02341

Analysis Method

HPLC,NMR,MS

Specification

97%

Storage

2-8°C

Molecular Weight

322.48

Appearance

Powder

Botanical Source

Structure Type

Diterpenoids

Category

Standards;Natural Pytochemical;API

SMILES

CC(=CCC1C2(CCCC(C2C(C(C1(C)O)O)O)(C)C)C)C=C

Synonyms

(1R,2S,3S,4R,4aS,8aS)-3,4a,8,8-Tetramethyl-4-[(2E)-3-methyl-2,4-pentadien-1-yl]decahydro-1,2,3-naphthalenetriol/1,2,3-Naphthalenetriol, decahydro-3,4a,8,8-tetramethyl-4-[(2E)-3-methyl-2,4-pentadien-1-yl]-, (1R,2S,3S,4R,4aS,8aS)-

IUPAC Name

(1R,2S,3S,4R,4aS,8aS)-3,4a,8,8-tetramethyl-4-[(2E)-3-methylpenta-2,4-dienyl]-2,4,5,6,7,8a-hexahydro-1H-naphthalene-1,2,3-triol

Density

1.0±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

174.5±19.2 °C

Boiling Point

408.5±30.0 °C at 760 mmHg

Melting Point

InChl

InChI=1S/C20H34O3/c1-7-13(2)9-10-14-19(5)12-8-11-18(3,4)16(19)15(21)17(22)20(14,6)23/h7,9,14-17,21-23H,1,8,10-12H2,2-6H3/b13-9+/t14-,15-,16+,17+,19-,20+/m1/s1

InChl Key

JEZOMVOAWYLQAJ-SKDBMBEJSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:70387-38-1) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

31956280

Abstract

Purpose
The Japan Society of Obstetrics and Gynecology (JSOG) has collected cycle?based assisted reproductive technology (ART) data in an online registry since 2007. Herein, we present the characteristics and treatment outcomes of ART cycles registered during 2017.

Methods
We collected cycle?specific information for all ART cycles implemented at participating facilities and performed descriptive analysis.

Results
In total, 448,210 treatment cycles and 56,617 neonates (1 in 16.7 neonates born in Japan) were reported in 2017, increased from 2016; the number of initiated fresh cycles decreased for the first time ever. The mean patient age was 38.0 years (standard deviation 4.6). A total 110,641 of 245,205 egg retrieval cycles (45.1%) were freeze?all cycles; fresh embryo transfer (ET) was performed in 55,720 cycles. A total 194,415 frozen?thawed ET cycles were reported, resulting in 66,881 pregnancies and 47,807 neonates born. Single ET (SET) was performed in 81.8% of fresh transfers and 83.4% of frozen cycles, with singleton pregnancy/live birth rates of 97.5%/97.3% and 96.7%/96.6%, respectively.

Conclusions
Total ART cycles and subsequent live births increased continuously in 2017, whereas the number of initiated fresh cycles decreased. SET was performed in over 80% of cases, and ET shifted from using fresh embryos to frozen ones.

KEYWORDS

ART registry, freeze?all strategy, in vitro fertilization, intracytoplasmic sperm injection, Japan Society of Obstetrics and Gynecology

Title

Assisted reproductive technology in Japan: A summary report for 2017 by the Ethics Committee of the Japan Society of Obstetrics and Gynecology

Author

Osamu Ishihara, 1 Seung Chik Jwa,corresponding author 1 Akira Kuwahara, 2 Yukiko Katagiri, 3 Yoshimitsu Kuwabara, 4 Toshio Hamatani, 5 Miyuki Harada, 6 and Tomohiko Ichikawa 7

Publish date

2020 Jan;

PMID

27099642

Abstract

Background
To date, several randomized controlled trials (RCTs) have shown the efficacy of repetitive transcranial magnetic stimulation (rTMS) in the treatment of major depression.

Objective
This analysis examined the antidepressant efficacy of rTMS in patients with treatment-resistant unipolar depression.

Methods
A literature search was performed for RCTs published from January 1, 1994, to November 20, 2014. The search was updated on March 1, 2015.

Two independent reviewers evaluated the abstracts for inclusion, reviewed full texts of eligible studies, and abstracted data. Meta-analyses were conducted to obtain summary estimates. The primary outcome was changes in depression scores measured by the Hamilton Rating Scale for Depression (HRSD), and we considered, a priori, the mean difference of 3.5 points to be a clinically important treatment effect. Remission and response to the treatment were secondary outcomes, and we calculated number needed to treat on the basis of these outcomes. We examined the possibility of publication bias by constructing funnel plots and by Begg’s and Egger’s tests. A meta-regression was undertaken to examine the effect of specific rTMS technical parameters on the treatment effects.

Results
Twenty-three RCTs compared rTMS with sham, and six RCTs compared rTMS with electroconvulsive therapy (ECT). Trials of rTMS versus sham showed a statistically significant improvement in depression scores with rTMS (weighted mean difference [WMD] 2.31, 95% CI 1.19-3.43; P < .001). This improvement was smaller than the pre-specified clinically important treatment effect. There was a 10% absolute difference between rTMS and sham in the rates of remission or response. This translates to a number needed to treat of 10. Risk ratios for remission and response were 2.20 (95% CI 1.44-3.38, P = .001 and 1.72 [95% CI], 1.13-2.62, P = .01), respectively, favouring rTMS. No publication bias was detected. Trials of rTMS versus ECT showed a statistically and clinically significant difference between rTMS and ECT in favour of ECT (WMD 5.97, 95% CI 0.94-11.0, P = .02). Risk ratios for remission and response were 1.44 (95% CI 0.64-3.23, P = .38) and 1.72 (95% CI 0.95-3.11, P = .07), respectively, favouring ECT. Conclusions Overall, the body of evidence favoured ECT for treatment of patients who are treatment-resistant. Repetitive transcranial magnetic stimulation had a small short-term effect for improving depression in comparison with sham, but follow-up studies did not show that the small effect will continue for longer periods.

Title

Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Author

Health Quality Ontario

Publish date

2016;

PMID

28331668

Title

Is Completion Axillary Dissection Necessary for This Patient?

Author

Sadullah Girgin,1 Atilla Soran,2 Nilufer Guler,3 Maktav Dincer,4 and Gokhan Demir5

Publish date

2014 Jul;